Manufacturing Equipment, Biologics

AkesoBio’s expanded manufacturing capacity, enabled by the addition of another Cytiva FlexFactory platform, will be used to meet current and future market needs in China as well as worldwide.

The new facility, which will be Evotec’s first in Europe, will aim to offer capacity, flexibility, and quality for biotherapeutic development and manufacturing while utilizing technology that employs small, automated, highly intensified, and continuous bioprocessing operations inside autonomous cleanrooms.

Catalent’s new mammalian cell culture suites in Madison, Wis. use single-use bioreactor systems for CGMP clinical and commercial manufacturing.

A series of minute virus of mice spiking studies were performed with a monoclonal antibody product and small-scale AEX membrane adsorbers to evaluate a range of critical processing conditions.

Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.

While manufacturing increases have been implemented for vials and syringes, meeting future market needs remains unpredictable.

The VerderFlex Vantage 5000 peristaltic pump is suitable for low to medium flow at low to medium pressures.

Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.

The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe.

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

The new facility at the company’s San Diego, CA, site will be for late phase and commercial CGMP manufacturing.

Cytiva will provide the first FlexFactory to be used in the manufacture of pDNA to Akron Bio.

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

The increased use of single-use bags in biologic manufacturing poses the risk of pinholes and other defects that cannot currently be tested for.

As technology matures, inefficiencies and process limitations in downstream process chromatography are improved.

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

It is critical to evaluate specific considerations, from design to application, for the benefit of downstream bioprocessing and manufacturing.

Ori Biotech is partnering with manufacturers and materials suppliers to develop an automated system for cell and gene therapy manufacturing.

Pumps and other components meet the demands of single-use systems in biopharmaceutical downstream processing.

The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.

Single-use and modular systems will meet demand for rapid implementation at different scales.

The expansion gives the company diversified capacity running cell production lines featuring Sartorius-brand 2000-L disposable bioreactors and now GE-brand 2000-L single-use bioreactors.

Industry experts debate the pros and cons of “going bigger” than the 2000-L industry norm in a single vessel.